Novartis India today reiterated its stance that the interpretation of enhanced efficacy under Indian Patent Act's section 3(D) remains unclear, reports Archana Shukla of CNBC-TV18. Earlier this month the Supreme Court had dismissed Novartis' plea...
08.10 | 0
komentar | Read More